Closed · RFA-FD-11-026 · CFDA 93.103 · Discretionary
Advancing Regulatory Science Through Development of Innovative Methodologies in the area of Antimicrobial Development (U01)
Federal grant opportunity posted by Food and Drug Administration, cataloged on Grants.gov.
- $50K-$100K
- Award range
- Closed
- Status
- July 2, 2011
- Close date
- 6
- Expected awards
The verdict
Advancing Regulatory Science Through Development of Innovative Methodologies in the area of Antimicrobial Development (U01) is a closed discretionary listing from Food and Drug Administration that offered $50,000 -- $100,000 across 6 expected awards. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 481 other opportunities from Food and Drug Administration.
- $50K-$100K
- award range
- Closed
- application status
- 6
- expected awards
- 93.103
- CFDA program
Archived opportunity record
Advancing Regulatory Science Through Developm… is closed (last close July 2, 2011). The parent program page for CFDA 93.103 is the reliable place to catch re-announcements. Food and Drug Administration still indexes 481 other opportunities here.
According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.
Deadline tracker
Application window closed
Closed July 2, 2011
Est. Total Funding
$500,000
Expected Awards
6
Instrument
Cooperative Agreement
Description
PLEASE NOTE: The correct contact information for the project officer is as follows: Nancy Masiello Telephone: 301-796-8498 and FAX: 301-847-8614. FDA is announcing an FOA for research into innovative methodologies in the area of antimicrobial development that can have an impact on the selection of the appropriate dosing and/or combination regimens to prevent emergence of antimicrobial resistance.This FOA is part of the Critical Path Initiative's (CPI's) long-term strategic effort to drive innovation in medical product development. CPI forms a key component of a broader FDA initiative, Advancing Regulatory Science, which focuses on developing new tools, standards, and approaches to assess the safety, efficacy, quality and performance of all FDA-regulated products.There is growing concern over the development of antimicrobial resistance. Even newer antimicrobials such as fluoroquinolones which formerly showed excellent broad spectrum activity are losing their value as the prevalence of resistant organisms continues to increase. Strategies have been explored to curtail the development of resistance. These range from restricting the use of certain antimicrobials, to elaborate infection control measures to prevent the spread of these organisms, to programs for antimicrobial stewardship.Mounting evidence suggests that combinations of antimicrobials and/or high dose and short duration therapy are promising strategies to combat the emergence of resistance. High drug exposure is often necessary to suppress the emergence of resistance and can involve increase in dose, or dosing frequency, or changes in the method of dose administration (e.g., extending infusion time). Combination antimicrobial therapy might prevent emergence of resistance by acting on multiple bacterial targets while simultaneously reducing the effective dose of individual drugs.The use of combination antimicrobials to prevent emergence of resistance and improve patient outcomes is standard practice in the treatment of tuberculosis, H. pylori, HIV, and currently malaria.The development of new antibacterial agents typically focuses on primary efficacy and the generation of resistance has not been a major consideration. This approach carries a legacy of failure with widespread resistance to almost all available agents.The purpose of this FOA is to investigate the potential value of novel PK/PD-based dosing and combination therapy approaches in preventing the development of antimicrobial resistance.[4] New modeling systems, such as in vitro hollow fiber systems, may be helpful in clarifying the potential value of these approaches. Areas of primary concern are Gram-negative pathogens that are frequent in health care settings as well as in the community, and are commonly treated with single agents, e.g. pathogens responsible for uncomplicated urinary tract infections. Many of these organisms, including E. coli, K. pneumoniae, Serratia, Acinetobacter, Proteus, P. aeruginosa, and Enterobacter spp., exhibit growing resistance to multiple antimicrobial agents.
Campus–civic applicant bridge · 4 doors
Advancing Regulatory Science Through Developm… bridges educational institutions with civic applicant types (4 doors: Public / state-controlled institutions of higher education; Nonprofits with 501(c)(3) status (other than IHEs); Private institutions of higher education; Others (see official listing text)). Expect campus and public/nonprofit operators in the same printed set. The extract does not mark applicant cost-sharing as required. Instrument: Cooperative Agreement. Funding-activity codes span Health · Science and Technology / R&D (HL;ST). Inside Food and Drug Administration's indexed book this exact eligibility-code string is unique to this listing.
- Code 06
- Public / state-controlled institutions of higher education
- Code 12
- Nonprofits with 501(c)(3) status (other than IHEs)
- Code 20
- Private institutions of higher education
- Code 25
- Others (see official listing text)
Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Parent Grant Program
Food and Drug Administration Research
U.S. Department of Health and Human Services
Agency Contact
Gladys Melendez Grants Management Specialist Phone 301-827-7168
More from Food and Drug Administration
Federal and University Partnership to Improve the Safety of Seafood from the Gulf of America
Research, Education, and Outreach on Botanical Natural Products
Cooperative Agreement to Support Shellfish Safety Assistance Project
Education and Outreach to Tribal Producers through the Tribal Food Safety Alliance
Use of Digital Health Technologies in Clinical Investigations to Support Drug and Biological Product Development (U01) Clinical Trials Optional
What to do next
Advancing Regulatory Science Through Developm… is closed; use the parent program and agency catalog for the next funding cycle.
- Parent CFDA 93.103 may publish future NOFOs under the same assistance listing. Open program
- Food and Drug Administration Research indexes 42 Grants.gov listings in this extract. Program profile
- Food and Drug Administration lists 481 other indexed opportunities on PlainGrants. Agency catalog
Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |